Nektar Therapeutics buy Heureka
Start price
13.01.20
/
50%
€23.50
Target price
09.03.20
€55.00
Performance (%)
-33.65%
End price
09.03.20
€15.59
Summary
This prediction ended on 09.03.20 with a price of €15.59. The BUY prediction by Heureka for Nektar Therapeutics performed very badly with a performance of -33.65%. Heureka has 50% into this predictionNektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Nektar Therapeutics | -8.947% | -8.947% | 115.517% | -92.153% |
iShares Core DAX® | -1.816% | -2.419% | 12.070% | 14.356% |
iShares Nasdaq 100 | 4.333% | 8.073% | 32.493% | 59.393% |
iShares Nikkei 225® | 0.657% | 1.234% | 2.682% | 5.342% |
iShares S&P 500 | 2.968% | 4.613% | 26.496% | 49.719% |
Comments by Heureka for this prediction
In the thread Nektar Therapeutics diskutieren
Buy mit Kursziel 55,0
In the thread Trading Nektar Therapeutics
Buy beendet